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Background: Human tuberculosis (TB) is caused by a plethora of Mycobacterium tuberculosis complex (MTBC)
strains belonging to seven phylogenetic branches. Lineages 2, 3 and 4 are considered “modern” branches of
the MTBC responsible for the majority of worldwide TB. Since the current BCG vaccine confers variable pro-
tection against pulmonary TB, new candidates are investigated. MTBVAC is the unique live attenuated vac-
cine based onM. tuberculosis in human clinical trials.
Methods: MTBVAC was originally constructed by unmarked phoP and fadD26 deletions in a clinical isolate
belonging to L4. Here we construct new vaccines based on isogenic gene deletions in clinical isolates of the
L2 and L3 modern lineages. These three vaccine candidates were characterized at molecular level and also in
animal experiments of protection and safety.
Findings: Safety studies in immunocompromised mice showed that MTBVAC-L2 was less attenuated than
BCG Pasteur, while the original MTBVAC was found even more attenuated than BCG and MTBVAC-L3 showed
an intermediate phenotype. The three MTBVAC candidates showed similar or superior protection compared
to BCG in immunocompetent mice vaccinated with each MTBVAC candidate and challenged with three rep-
resentative strains of the modern lineages.
Interpretation: MTBVAC vaccines, based on double phoP and fadD26 deletions, protect against TB indepen-
dently of the phylogenetic linage used as template strain for their construction. Nevertheless, lineage L4 con-
fers the best safety profile.
Funding: European Commission (TBVAC2020, H2020-PHC-643381), Spanish Ministry of Science (RTI2018-
097625-B-I00), Instituto de Salud Carlos III (PI18/0336), Gobierno de Aragon/Fondo Social Europeo and the
French National Research Council (ANR-10-LABX-62-IBEID, ANR-16-CE35-0009, ANR-16-CE15-0003).
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Tuberculosis (TB) is the most devastating disease caused by a sin-
gle infectious agent over the last 200 years [1]. In 2018, theWHO esti-
mated 10 million new TB cases and more than 1.4 million deaths
caused by TB [2].
TB is principally caused in humans by Mycobacterium tuberculosis
and Mycobacterium africanum, classified within the M. tuberculosis
Research in context
Evidence before this study
Current vaccines against pneumococci, meningococci, influenza or
polio are designed taking into account the existing pathogen vari-
ability. However, to our knowledge, none of the existing TB vaccine
candidates that aim to improve the efficacy of the current vaccine
BCG, have addressed vaccine efficacy taking into consideration the
evolutionary landscape of TB-causing bacteria. Indeed, TB vaccine
candidates under clinical development have exclusively demon-
strated protection againstM. tuberculosis strains belonging to a sin-
gle lineage, of the seven existing phylogenetic lineages, of this
pathogen. Since 2012, a live vaccine based on attenuated M. tuber-
culosis (MTBVAC) is in Phase 1 and Phase 2 clinical trials in new-
borns and adults and in 2021will be ready for efficacy studies.
Added value of this study
In this manuscript, we reappraise TB vaccine efficacy in the con-
text of the evolutionary genomics of M. tuberculosis. Here, we
construct and characterize live attenuated vaccines based on
MTBVAC in the three modern lineages of M. tuberculosis, which
represent the majority of circulating strains worldwide. This
MTBVAC set is subsequently tested in mouse models of safety
and protective efficacy against challenge with three representa-
tive strains from each modern lineage. Notably, this is the first
time demonstrating that a live attenuated vaccine in clinical
development is able to protect mice against pathogens from
the most prevalent lineages, a result translationally relevant for
the future efficacy trials with MTBVAC. Additionally, this is the
first time to study how the genetic background impacts on
safety and protective efficacy of live attenuated TB vaccines.
Implications of all the available evidence
With this study, we aim to anticipate future TB efficacy trials. This
study provides proof-of-concept withMTBVAC andwe aim to stab-
lish recommendations for other vaccine candidates in the pipeline.
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ally, zoonotic TB in humans caused by animal-adapted members of
the MTBC is also observed [6]. Human-adapted mycobacteria can be
classified in “ancestral“ or “modern” lineages based on the presence
or absence of the M. tuberculosis specific deletion region TbD1 [7,8].
Lineages that harbor the TbD1 region include lineages 1 and 7 of M.
tuberculosis, and lineages 5 and 6 of M. africanum. These are referred
as ancient lineages and they are geographically restricted to specific
areas, except for lineage 1, which shows an intermediate distribution,
with main prevalence in South India and South East Asia [4,9]. By
contrast, M. tuberculosis lineage 2, which are also known as repre-
senting Beijing strains, lineage 3 strains, known also as CAS/Dehli
strains and lineage 4, corresponding to the Euro-American strain
families are considered as modern lineages and they include world-
wide distributed strains [9]. The widespread distribution of modern
lineages probably reflects the adaptive evolution of the MTBC to
transmit and cause disease in crowded, dense and urbanized popula-
tions, a hypothesis that was recently supported by data on increased
resistance of modern lineages to oxidative stress and hypoxia relative
to L1 strains [8]. As such, there is converging evidence from epidemi-
ologic and experimental data, which suggests that strains from line-
ages 2, 3 and 4, have become more successful in terms of their
geographical distribution, being responsible for a large proportion of
the global TB burden [9].The only vaccine licensed against TB is the Bacille Calmette and
Guerin (BCG), which was obtained after in vitro passaging of Myco-
bacterium bovis -the causative agent of bovine TB- for 13 years at the
beginning of the 20th century [10]. Loss of Region of Difference 1
(RD1) with respect to the MTBC members, substantially contributes
to BCG attenuation [11,12]. This region codes for genes of the ESX-1
protein complex responsible for the co-secretion of ESAT-6 and CFP-
10. Both proteins are major antigens of M. tuberculosis. Specifically,
ESAT-6, secreted by ESX-1 type VII secretion system, has been exten-
sively documented as a putative virulence and immunogenicity factor
of MTBC pathogens. Among the various putative functions of ESAT-6,
its implication in phagosomal rupture within infected phagocytes, is
of particular interest, and enables ESX-1 proficient strains to get in
contact with the host cytosol [13,14]. BCG was administered for the
first time in 1921 and during the next decades BCG sub-strains
emerged as a consequence of the parallel in vitro sub-cultivation of
the original BCG in different laboratories [10,15]. BCG confers protec-
tion from the severe forms of the disease in children although protec-
tion against pulmonary TB in adolescents and adults is considerably
variable [16]. Consequently, this main limitation of BCG to stop TB
transmission imposes a priority in the research of new vaccines can-
didates. A rationale vaccine research requires to understand the
MTBC virulence factors and immunogenicity conferred by mycobac-
terial components [17]. Today, a wide pipeline of vaccine candidates
targeting different populations is currently in clinical trials including
live attenuated vaccines, adjuvanted protein subunit vaccines, viral-
vectored vaccines and whole cell inactivated vaccines [18].
MTBVAC is currently the unique live vaccine candidate in clinical
development which is based on an attenuated strain of the human
pathogenM. tuberculosis. MTBVAC consists on the unmarked deletion
of phoP and fadD26 genes in the clinical M. tuberculosis isolate Mt103,
representing a lineage 4 strain [19] .
The gene phoP encodes the transcription factor of the Two-Com-
ponent System PhoPR, which controls approximately 2% of the
genome content ofM. tuberculosis [2023]. The PhoP regulon orches-
trates diverse networks in M. tuberculosis, including the secretion of
the ESAT-6 [24], the synthesis of sulfolipid and di- and polyacyltreha-
loses [25], the expression of the non-coding RNA mcr7, impacting the
activity of the Twin Arginine Translocation (Tat) secretion apparatus
[23] and production of phosphatidylinositol mannosides [26]. The
gene fadD26 is the first gene in an operon required for the synthesis
of phthiocerol dimycocerosates (PDIM) [27], mycobacterial virulence
lipids that are involved in phagosomal rupture in concert with ESAT-
6 [2830]. Since MTBVAC is derived from an M. tuberculosis clinical
isolate, it conserves the whole T cell epitope repertoire described for
MTBC pathogens including the major immunodominant antigens
ESAT-6, CFP-10 and PPE68 absent in BCG as a consequence of the
RD1 deletion. These three proteins, albeit small, are unusually immu-
nogenic and contain 285 of the total 1.603 epitopes described in M.
tuberculosis [31]. In line with this observation, our recent preclinical
studies have demonstrated that immunity against ESAT-6 and CFP-
10 conferred after MTBVAC vaccination remarkably correlate with
improved vaccine efficacy relative to BCG Danish [32].
After an extensive preclinical testing in animal models [19,3336],
MTBVAC was the first and unique live attenuated M. tuberculosis vaccine
approved to enter into clinical trials in 2012 [37]. After successfully com-
pleted phases Ia (NCT02013245) [38] and Ib (NCT02729571) [39], cur-
rently, two phases IIa trials are ongoing in South Africa, one in newborns
using MTBVAC as a prime vaccine (NCT03536117) and the other on in
adults whereMTBVAC is tested as a boost for BCG (NCT02933281).
In this study, we reappraise vaccine efficacy of newly constructed
MTBVAC variants in the context of the global genetic diversity of the
MTBC. The main aims of the study are linked to the question whether
the original MTBVAC is able to protect against the three modern line-
ages of the MTBC or whether a vaccine candidate constructed in a spe-
cific lineage might lead to lineage-dependent improved protection.
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2.1. Bacteria and culture conditions
M. tuberculosis strains used in this work are detailed in Table S1.
Briefly, GC1237 [40], HMS13037 (a clinical isolate from our labora-
tory collection belonging to lineage 3 of M. tuberculosis), Mt103 [41],
their respective phoP-fadD26 mutants, H37Rv [42], W4 (kindly pro-
vided by Gilla Kaplan) [43], HCU3524 (a clinical isolate from our labo-
ratory collection belonging to lineage 3) and BCG Pasteur 1173P2,
were grown in liquid media at 37 °C with Middlebrook 7H9 broth
(Difco) supplemented with 10% (vol/vol) of ADC (0.5% bovine serum
albumin, 0.2% dextrose, 0.085% NaCl and 0.0003% beef catalase) and
0.05% (vol/vol) Tween-80. For solid media, Middlebrook 7H10 (Difco)
supplemented with ADC, except for the HMS13037 strain, supple-
mented with OADC (ADC with 0.005% (vol/vol) oleic acid) was used.
When required, hygromycin (Hyg) 20 mg/ml or Kanamycin (Km)
20 mg/ml were added. Escherichia coli strains (MC1061, DH5a,
DH10B, XL1-BLUE or BW25141) were grown in liquid media at 37 °C
in Luria-Bertani (LB) broth. When required, ampicillin (Amp) 100 mg/
ml, Km 20 mg/ml, Hyg, 50 mg/ml or chloramphenicol (Cm), 12.5 mg/
ml were added. On solid media, LB-agar was used.
2.2. Construction of fadD26 and phoPmutants
Isogenic deletions in fadD26 and phoP genes present in the origi-
nal MTBVAC vaccine [19] were obtained in GC1237 and HMS13037
strains using two different approaches: suicide plasmids and BAC-rec
(see Table S2 for extended information about the vectors used). Sui-
cide plasmid pAZ5 was used to obtain the fadD26 deletion in GC1237
and pAZ18 was used to construct the phoP deletion in GC1237 and
HMS13037 as described in Arbues and colleagues [19]. pAZ5 and
pAZ18 harbor fadD26 and phoP genes interrupted with the res-Hyg-
res cassette respectively, Gentamicin resistance gene cassette,
reporter gene xylE and the counter selectable marker sacB. Single
recombinants were selected by plating transformants in Hyg-con-
taining plates and testing positive XylE activity by addition of a cate-
chol solution (0.55 g of catechol dissolved in 47.5 ml of water and
2.5 ml of PBS). Single recombinants were grown in liquid media and
serial dilutions were plated onto 7H10 (ADC or OADC) containing 2%
of sucrose (Suc) and Hyg to select double recombinants. XylE nega-
tive clones were confirmed by PCR using primers 5upstream of
3downstream of the region cloned in the plasmid, in res sites or in
the gene deleted region. To remove the Hyg cassette, pAZ20 replica-
tive plasmid harbouring gd-resolvase, Km- and Gentamicin (Gm)-
cassette resistance and the counter selectable marker sacB was used
[19]. Unmarked deletion was confirmed by replica plating in Km, Hyg
and w/o antibiotic plates and by PCR using the appropriate primers
(Table S3). BAC-rec strategy was used to obtain fadD26 deletion in
HMS13037. A M. tuberculosis H37Rv bacterial artificial chromosome
(BAC) library obtained in the pBeloBAC11 vector contained in E. coli
DH10B was used [44]. The clone DH10B carrying the Rv209 BAC con-
taining the fadD26 (Rv2930) gene was selected and the thermosensi-
tive plasmid pKD46 carrying red recombinase from lambda phage
was co-transformed [45]. DH10 Rv209 pKD46 induced with arabi-
nose 0.15% was transformed with a PCR product (using fadD26-P1-
Fw and fadD26-P2 primers) containing the FRT-Km-FRT-cassette
from pKD4 flanked with 40 bp of identity arms to target the fadD26
gene. Gene deletion in the BAC was confirmed by PCR amplification
using specific primers. BAC Rv209-DfadD26::Km was used as tem-
plate to obtain the allelic exchange substrate (AES) using KO-fadD26-
Fw and KO-fadD26-Rv primers to transform in mycobacteria. AES
consists on the FRT-Km-FRT cassette flanked with 700 pb of identity
arms of the specific site of recombination and was transformed in
HMS13037 strain harbouring pJV53H (induced with 0.2% of acet-
amide) [46]. Recombinants were plated onto Km-containing platesand were confirmed using appropriate primers. Loss of pJV53H plas-
mid was confirmed by replica plating onto Hyg and Km. To unmark
the deletion, pRES-FLP-Mtb plasmid (HygR) harbouring the flp recom-
binase from Saccharomyces cerevisiae with adapted codons for M.
tuberculosis [47]. Transformants were selected in Hyg-containing
plates and the removal of the cassette was confirmed by replica plat-
ing and PCR amplification using fadD26F and fadD26R primers. Loss
of pRES-FLP-Mtb plasmid was confirmed by replica plating.
2.3. Protein extraction and Western blotting
Cultures were grown in 7H9-0.05% Tween-80 supplemented with
dextrose, NaCl and catalase to avoid albumin contamination in the
secreted fraction. Bacteria were grown until an OD of 0.60.8 at 37 °C
and pelleted. Supernatant fractions were filtered through a 0.22 mm-
pore-size filter and incubated on ice for 2 h with 10% (vol/vol) of tri-
chloroacetic acid. Sampled were centrifuged for 1 h at 4 °C and pellets
were washed with acetone. Supernatants were discarded after centrifu-
gation and pellets were air dried and dissolved in Tris 150 mM pH 8.8.
For whole-cell protein extractions, bacteria were resuspended in PBS
containing 1% Triton X-100 and transferred into tubes containing glass
beads (MP Biomedicals). Suspensions were disrupted by Fast-Prep
(6.5 m/s, 45 s) twice and samples were cooled on ice between the cycles.
Supernatants containing soluble proteins were filtered through a
0.22 mm-pore-size filter were after centrifugation. Protein extractions
were quantified using QuantiPro BCA assay (Sigma Aldrich). Samples
were heated for 10 min at 100 °C after adding Laemmli buffer and sam-
ples were loaded in 1217% polyacrylamide gels containing 0.1% SDS.
Then, proteins were transferred to a PDFV membrane using a semi-dry
electrophoretic transfer cell (Trans-Blot Semi-Dry Transfer cell, Bio-
Rad). Proteins were blocked with 5% (w/v) skimmed milk in TBS-T
buffer (25 mM Tris pH = 7.5, 150 mMNaCl, 0.05% Tween 20) for 30 min
and incubated overnight with the primary antibody. Membranes were
then washed with TBS-T buffer before incubation with secondary anti-
bodies for 1 h. Membranes were washed and signals were detected
using chemiluminescent substrates (Western BrightTM Quantum,
Advansta). Immunodetection was carried out using PhoP-antiserum
(1:5000), antibodies anti-sigA and anti-CFP-10 (Thermo Scientific) (both
at 1:5000) followed with the incubation with secondary antibody anti-
rabbit IgG human serum adsorbed conjugate (1:5000) (KPL) or incuba-
tion with monoclonal antibody anti-ESAT-6 (1:2500) (abcam), anti-
GroEL2 (Hsp65) (1:2500) (Invitrogen) or anti-PE_PGRS (1:2000)
(described in [48,49]), followed by incubation with an anti-mouse IgG
human serum adsorbed conjugate (1:5000) (KPL). To reprove blots,
ReBlot Plus Strong Antibody Stripping Solution (Millipore) was used fol-
lowing the specification sheet.
2.4. RNA extraction and qRT-PCR
Bacteria were pelleted and resuspended in 250 ml in wash buffer
(aqueous solution containing 0.137 M NaCl and 0.5% Tween 80) and
500 ml of RNA protect reagent (Quiagen) to avoid RNA degradation.
Suspensions were centrifuged after 5-minute incubation at room
temperature. Pellets were dissolved in lysis buffer (20 mM sodium
acetate, 0.5% SDS, 0.1 mM EDTA) and 1 ml of phenol:chloroform
(5:1), pH = 4.5. Bacterial suspensions were transferred into tubes con-
taining glass beads (MP Biomedicals) and cells were lysed by Fast-
Prep (2 cycles, 45 s at speed 6.5 m/s, samples were cooled on ice
between cycles). Tubes were centrifuged and aqueous phases were
transferred to a tube containing chloroform:isoamylic alcohol (24:1).
After centrifugation upper phases were transferred to a tube contain-
ing isopropanol and 0.3 M sodium acetate (pH = 5.5) and tubes were
incubated at 20 °C overnight. After centrifugation at 4 °C, precipi-
tated nucleic acids were collected and pellets were washed with eth-
anol 70%. Samples were again centrifuged and pellets were dissolved
in diethylpyrocarbonate (DEPC)-treated water (RNase free). DNA was
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DNA-free (Ambion) by addition of 1ml of DNase. Later, RNA was puri-
fied by adding phenol:chloroform (5:1) pH = 4.5, and previous steps
were repeated to precipitate, collect, dry and dissolve the RNA in
DEPC-treated water. RNA integrity was confirmed by agarose gel
electrophoresis and absence of DNA was confirmed by absence of
amplification products after PCR. Reverse transcription was per-
formed using PrimeScriptTM RT Reagent Kit as detailed in the product
manual. qRT-PCR reaction was performed in the StepOne Plus Real
Time PCR System (Applied Biosystems) using TB Green Premix Ex
TaqTM (Tli Rnase H Plus) (Takara) kit. For the reaction, primers at a
final concentration of 0.25 mM and cDNA diluted 1:10 were used.
Normalization was calculated using the sigA housekeeping gene in
each sample. Absence of unspecific PCR products were confirmed
after examination of melting curves in each sample.
2.5. Neutral red staining
Bacteria grown on solid media were transferred to a tube contain-
ing 50% of methanol in water. Supernatants were discarded after 1 h
of incubation. Pellets were resuspended in 750 ml of barbital buffer
(1% sodium barbital in 5% NaCl, pH 9.8). After centrifugation, bacteria
were resuspended in 4 ml of barbital buffer. 150 ml of a solution of
0.05% neutral red in barbital buffer were added and incubated at 37 °
C for 1 h. After incubation, supernatants were discarded to evaluate
the staining of the pelleted bacteria.
2.6. Mouse infection
Allmicewere observed and kept under controlled conditions. For pro-
tective efficacy experiments, eight-week old immunocompetent C3H/
HeNRj female mice were vaccinated subcutaneously with 106 CFU in
100 ml of PBS. Mice were vaccinated with BCG Pasteur, MTBVAC,
MTBVAC-L2::hyg or MTBVAC-L3::hyg, or unvaccinated as control group.
Eight weeks later, mice were challenged by intranasal route with 200
CFU in 40 ml of PBS of eachM. tuberculosis strain belonging to one of the
modern lineages (W4, HCU3524 or H37Rv belonging to lineages 2, 3 and
4 respectively). Four weeks post-challenge, bacterial burden was evalu-
ated in lungs and spleen. Serial dilutions were plated onto 7H10-ADC. For
attenuation experiment, eight-week old immunocompromised SCID
female mice were inoculated by intraperitoneal route with 106 bacteria
in 100 ml PBS, equivalent to 2 times the dose of BCG recommended for
humans. Mice were controlled and their weight was followed during the
experiment. Experimental endpoint was defined when loss of weight
wasmore than 20%.Fig. 1. Sequential genetic steps to construct unmarked DphoP DfadD26 mutants in M. tuberc
MTBVAC-L3. Those steps involving the use of suicide plasmids pAZ5 or pAZ18 are colored in
FRT sites used for resolution of the hygromycin and kanamycin cassettes are indicated by b
and/or Western-Blot (see Supplementary Material).2.7. Statistical analysis
For protection experiments, statistical analysis of CFUs in the
organs was performed using One-way ANOVA, Bonferroni post-test.
For safety experiments, the statistical analysis was calculated apply-
ing a Log-rank (Mantel-Cox) test.
2.8. Ethics statement
Experimental animal studies were performed in agreement with
European and national directives for the protection of animal for
experimental purposes. All procedures were carried out under Proj-
ect Licenses PI50/14 (protective efficacy) and PI33/15 (attenuation)
approved by the Ethic Committee for Animal Experiments from the
University of Zaragoza.
2.9. Role of the funding source
The funders had no role in study design, data collection and analy-
sis, decision to publish or preparation of the manuscript. The corre-
sponding author had full access to all the data in the study and had
final responsibility for the decision to submit for publication
3. Results
3.1. Construction of two new vaccine candidates based on isogenic phoP
and fadD26 deletions present in MTBVAC
Based on previous knowledge acquired during the preclinical and
clinical development of MTBVAC [3739], a live attenuated M. tuber-
culosis strain belonging to lineage 4 [19], we have introduced simul-
taneous phoP and fadD26 deletions in two clinical isolates belonging
to lineages 2 and 3 of M. tuberculosis. Our objective was to obtain a
set of isogenic MTBVAC-like vaccine candidates constructed in the
genetic backgrounds of the three modern lineages of M. tuberculosis.
M. tuberculosis GC1237 [40], which is a Beijing strain classified to the
Asian-Ancestral 3 sub-branch of lineage 2 strains [50] and the
HMS13037 clinical isolate, a lineage 3 isolate showing a CAS-1 Delhi
spoligotype, were selected as parental strains for the genetic con-
structions (Figure S1 and Table S1). To obtain double unmarked gene
deletions, two alternative and complementary strategies based on
suicide plasmids [19] or BAC-rec [32] were used. In the GC1237
strain, the fadD26 deletion was obtained using the suicide plasmid
pAZ5 followed by the phoP deletion using pAZ18 (Fig. 1a). In the
HMS13037 strain, BAC-rec was used to delete fadD26 and the suicideulosis strains from lineages 2 and 3. (a) Construction of MTBVAC-L2. (b) Construction of
brown and utilization of the BAC-rec strategy is indicated by green colors. The res and
rown and green open diamonds respectively. Each genetic step was confirmed by PCR
I. Perez et al. / EBioMedicine 55 (2020) 102761 5plasmid pAZ18 was used to construct the phoP deletion (Fig. 1b). The
antibiotic markers were subsequently eliminated using gd and FLP
recombinases suitable for the suicide plasmids and BAC-rec strategies
respectively (Fig. 1). Gene deletions were confirmed by PCR using
two pairs of primers flanking the mutation (Figure S2, S3 and S4,
Table S2), and the phoP deletion was additionally confirmed by West-
ern-blot (Figure S4). Altogether, two new double unmarked phoP and
fadD26 mutants were obtained and named MTBVAC-L2 and
MTBVAC-L3, for lineage 2 and 3 respectively (Fig. 1).
3.2. Molecular characterization of MTBVAC-L2 and MTBVAC-L3
demonstrate equivalent phenotypes described in MTBVAC
At first, PhoP-dependent phenotypes previously described for
MTBVAC were evaluated in the new vaccine candidates. A transcrip-
tomics approach was used to evaluate whether specific downregula-
tion of representative transcripts of the PhoP-regulon (mcr7, pks2
and pks3) [20,23] existed in MTBVAC-L2, MTBVAC-L3 and MTBVAC,
compared to their parental strains. For mcr7 and pks2 we observed
the expected downregulation in the three MTBVAC variants. Excep-
tionally, expression of pks3 in MTBVAC-L3 was slightly increased
compared to the parental HMS13037 strain (Fig. 2a), which might
indicate that subtle inter-lineage differences could exist in the PhoP
regulon. We also confirmed that MTBVAC, MTBVAC-L2 and MTBVAC-
L3 are unable to fix neutral red, contrasting to their parental strains
(Figure S5a). This phenotype is putatively related to the altered cell
envelope absent in PDIM and acyltrehalose-derived lipids, whose
synthesis involves fadD26 and phoP, respectively [19,25].
One of the best characterized phenotypes linked to PhoP, is its
involvement in regulation of the secretion of ESAT-6 [22,24,51]. West-
ern-blot analyses showed that ESAT-6 was only secreted in the parental
strains in contrast to MTBVAC, MTBVAC-L2 and MTBVAC-L3. Neverthe-
less, ESAT-6 was detected in the whole-cell lysate of both the parental
strains and the fadD26- and phoP-deleted strains (Fig. 2b). Despite the
inability of phoP-deletion mutants to secrete ESAT-6, it has been
recently described that MTBVAC is able to secrete CFP-10 [32], although
the mechanism of the process relative to the previously defined ESAT-6
and CFP-10 co-secretion [52], still needs to be defined. Here, we demon-
strate that MTBVAC-L2 and MTBVAC-L3, similar to classical MTBVAC,
does secrete CFP-10 into the supernatant (Fig. 2b).
RNA-seq of MTBVAC revealed that the operon formed by fadD26 and
downstream genes (ppsA-D) is substantially less expressed compared to
the Mt103 wild-type strain (Figure S6). We tried to confirm this result by
qRT-PCR of ppsA and ppsB genes in MTBVAC-L2 and MTBVAC-L3 com-
pared to their parental strains. The expected absence of the ppsAB tran-
scripts was observed in MTBVAC and MTBVAC-L2; however, we
observed similar levels of ppsAB in MTBVAC-L3 relative to the HMS13037
parental strain (Fig. 2d). This unexpected result might be related to the
genetic scar left in the chromosome after resolution of the antibiotic
resistancemarker and will be discussed below.
3.3. MTBVAC-L2 produces but does not secrete PE_PGRS proteins and
this phenotype is related to the lineage background used in genetic
constructions
The ppe38 locus is polymorphic in the Beijing family resulting in
deletion of the ppe38 gene at the branching point of the “modern”
Beijing sub-strains [53]. Deletion of ppe38 completely blocks the abil-
ity to secrete PE_PGRS proteins (a subfamily of PE proteins). Interest-
ingly, lack of secretion of these proteins has been associated with an
increased virulence of M. tuberculosis strains in mouse models [53].
Moreover, BCG strains were also shown to lack PE_PGRS secretion
due to the deletion of the RD5 region, although this absence had little
impact on the protective efficacy of BCG strains in mice [49]. To fur-
ther characterize the vaccine candidates MTBVAC, MTBVAC-L2 and
MTBVAC-L3, the organization of the ppe38 locus was studiedaccording to McEvoy and colleagues [54], indicating the putative
absence of the ppe38 gene in GC1237 (Figure S5). Indeed, PE_PGRS
proteins were detected by Western-blotting in the whole-cell frac-
tions of the three strains (Fig. 2c) using a specific antibody, whereas
PE_PGRS proteins were only detected in the supernatants of MTBVAC
and MTBVAC-L3 strains, and not in MTBVAC-L2 supernatant frac-
tions. Accordingly, here we confirm a differential phenotype between
MTBVAC-L2 and MTBVAC/MTBVAC-L3 strains, which is related to the
specific lineage used as background for vaccine construction.3.4. MTBVAC-L2 and MTBVAC-L3 are attenuated in SCID mice although
both showed less attenuation than MTBVAC
To evaluate the safety profile of the new MTBVAC candidates, a
survival experiment was performed in immunocompromised SCID
mice. To discard differences due to in vitro fitness of different vac-
cines, we first confirmed that MTBVAC-L2 and MTBVAC-L3 as well as
their parental strains exhibited comparable in vitro growth curves
(Figure S7).
Next, mice were inoculated with MTBVAC-L2 or MTBVAC-L3. BCG
Pasteur and the original MTBVAC strains were used as comparators.
MTBVAC-L2 and MTBVAC-L3 showed an attenuated profile in SCID
mice (mean of survival of 85.5 days in the former and 93.5 days in
the latter). Thus, MTBVAC-L3 exhibits comparable attenuation to BCG
Pasteur but MTBVAC-L2 is less attenuated than the currently licensed
BCG. Notably, of the three double phoP- and fadD26-deletion mutants
tested, the original MTBVAC was the most attenuated and even safer
than BCG Pasteur (Fig. 3).3.5. MTBVAC, MTBVAC-L2 and MTBVAC-L3 confer protection in mice
against modern strains ofM. tuberculosis and this phenotype is
unrelated to the lineage used for vaccine construction
According to previous research, greater protection of MTBVAC rel-
ative to BCG Danish was observed in C3H/HeNRj mice with respect to
other commonly used mouse strains such as C57BL/6 or BALB/c 32.
This phenotype is likely attributable to the H-2k haplotype of the
Major Histocompatibility Complex present in the C3H/HeNRj mouse
strain, which is able to recognize both ESAT-6 and CFP-10 immuno-
gens, in contrast to the H-2b haplotype in C57BL/6 mice that only rec-
ognizes ESAT-6, and/or the H-2d haplotype in BALB/c mice which
does neither recognizes ESAT-6, nor CFP-10. Accordingly, the C3H/
HeNRj model was considered as useful to discriminate the protective
efficacy of MTBVAC compared to BCG [32]. In this study, we used the
C3H/HeNRj mouse model to compare protective efficacy of MTBVAC,
MTBVAC-L2 and MTBVAC-L3 against challenge with M. tuberculosis
strains belonging to the modern lineages of the MTBC. For intranasal
challenge, M. tuberculosis strains H37Rv (lineage 4), W4-Beijing (line-
age 2) and HCU3524 (lineage 3) were used. The licensed vaccine BCG
Pasteur 1173P2 was used as comparator, since this strain is widely
used in animal experiments. Enumeration of bacterial burden in
lungs and spleens showed that the three MTBVAC strains conferred
similar protection against challenge with isolates belonging to mod-
ern lineages. After challenge with H37Rv, all vaccines tested con-
ferred similar protection against lineage 4 (Fig. 4a). Challenge with a
Beijing strain resulted in significant increased protection of animals
previously vaccinated with MTBVAC and MTBVAC-L2 compared to
BCG Pasteur (Fig. 4b). Variable protection was observed against chal-
lenge with lineage 3, the lowest bacterial burden in lungs was
observed for vaccination with MTBVAC and MTBVAC-L3, followed by
MTBVAC-L2 and BCG Pasteur (Fig. 4c). Noteworthy, the three
MTBVAC vaccines exhibited comparable protection against each chal-
lenge strain, indicating that protective efficacy phenotypes are inde-
pendent of the lineage used as MTBVAC background.
Fig. 2. Molecular characterization of MTBVAC, MTBVAC-L2 and MTBVAC-L3. (a) Expression of representative genes from the PhoP-regulon (mcr7, pks2 and pks3) measured by qRT-
PCR in MTBVAC, MTBVAC-L2 and MTBVAC-L3 compared to their respective parental strains. Each gene was normalized against sigA expression in each sample. Bars represent the
mean and standard deviation from three independent experiments. (b) Western-blot of ESAT-6 and CFP-10 proteins in whole-cell lysates (left panel) and secreted fractions (right
panel) in the MTBVAC vaccines and their wild type strains. Note the absence of ESAT-6 secretion as a consequence of the phoPmutation in all vaccine strains. Also note the presence
of CFP-10 in the secreted fraction in all MTBVAC strains. Detection of SigA and SigB serves as loading control in the whole-cell lysate and also as cell integrity control in the secreted
fraction. (c) Western-blot of PE_PGRS in total (left panels) and secreted fractions (right panel) from the MTBVAC vaccine set. Note the differential absence of PE_PGRS secretion in
MTBVAC-L2. (d) Expression of the ppsAB genes belonging to the PDIM biosynthetic operon measured by qRT-PCR. Bars represent the mean and standard deviation from three inde-
pendent experiments. Each sample was normalized relative to the endogenous control sigA.
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To achieve the end of TB, new tools including new effective vac-
cines, better diagnostics and new drugs are needed [55]. Despite the
diversity in vaccine strategies currently in clinical trials, preclinical
research on new live vaccines continues in order to keep the vaccine
pipeline filled. Recently, live vaccine candidates based on BCG [56,57]or attenuated M. tuberculosis [58] have been reported. Live attenu-
atedM. tuberculosis vaccines are expected to confer an effective T-cell
immune response since they maintain those antigens missing in RD
regions from BCG [31]. MTBVAC is one of the two live attenuated vac-
cine candidates currently in clinical trials, representing the unique
candidate based on genetic background of the human pathogen M.
tuberculosis. MTBVAC confer higher and more durable T-cell
Fig. 3. Attenuation of MTBVAC, MTBVAC-L2 and MTBVAC-L3 in the SCID mouse model. Survival curves from groups of 6 SCID mice inoculated by intraperitoneal route with
MTBVAC, MTBVAC-L2, MTBVAC-L3 and BCG Pasteur (as control) are shown. Asterisks indicate * p < 0.05, **p < 0.01 and *** p<0.001 [Log-rank (Mantel-Cox) test].
I. Perez et al. / EBioMedicine 55 (2020) 102761 7responses than BCG in a vaccinated human cohort [39] and this find-
ing might be related to the fact that MTBVAC contains approximately
a 50% broader antigenic repertoire of T-cell epitopes compared to
BCG [31]. However, the possible lineage-dependent protection of
MTBVAC remains unknown and its protective efficacy in animal mod-
els has been exclusively evaluated against M. tuberculosis H37Rv or
M. tuberculosis Erdman strains, both belonging to lineage 4 [19,36].
To evaluate lineage-dependent protection, we have constructed two
new vaccine candidates based on isogenic deletions ofMTBVAC in the lin-
eages 2 and 3 of M. tuberculosis (MTBVAC-L2 and MTBVAC-L3). As a
result, we have obtained the complete set of MTBVAC vaccines in the
three modern lineages of M. tuberculosis. Molecular characterization
of this vaccine set revealed that most PhoP- and FadD26-dependent phe-
notypes are maintained across lineages, although some differences were
observed. The most prominent PhoP-regulated genes (mcr7, pks2 and
pks3) are overall downregulated in the MTBVAC set. However, pks3
expression remained unchanged in MTBVAC-L3 compared to the paren-
tal strain. This unexpected finding opens new perspectives to decipher
whether the PhoP-regulon might be lineage-dependent. Indeed, similar
inter-strain differences have been recently observed in the PhoP regulon.
The whiB6 gene, which belongs to the PhoP regulatory network, is posi-
tively regulated by PhoP in Mt103 and GC1237 strains while negatively
regulated in H37Rv. This differential regulation is caused by a single
nucleotide insertion exclusively present in H37Rv and results in lower
ESAT-6 secretion in H37Rv relative to otherM. tuberculosis strains [51].
Another marked differential phenotype was observed in the
expression of the fadD26-ppsAD operon. The ppsAB genes are simi-
larly expressed in MTBVAC-L3 relative to the HMS13037 parental
strain in contrast to MTBVAC and MTBVAC-L2 when compared to
their respective parental strains. A closer inspection of the genetic
constructions suggests that the chromosomal “scar” after resolution
of the antibiotic markers is different between MTBVAC-L3 (FRT site)
and MTBVAC/MTBVAC-L2 (res site) (Fig. 1). Thus, the res site would
cause a polar effect in expression of the 3fadD26 downstream region.
By contrast, the FRT site contained in the fadD26 deleted gene in
MTBVAC-L3 is designed to create nonpolar effects, as described by
Datsenko and colleagues [45].
The two MTBVAC derivatives constructed here robustly reproduce
the presence of CFP-10 and the absence of ESAT-6 in the secreted pro-
tein fraction, previously documented for MTBVAC [32]. It is important
to mention that this phenotype could interfere with the diagnostic
potential of current interferon gamma release assays (IGRA) -which con-
tain ESAT-6 and CFP-10- as diagnostic antigens, as observed forMTBVAC-vaccinated newborns [39] and consequently, specific diagnos-
tic tools able to differentiate between MTBVAC-immunized and M.
tuberculosis-infected individuals are currently under study.
Preclinical safety experiments in immunodeficient mice revealed
that albeit the three MTBVAC derivatives were attenuated, inter-lineage
differences were found. Beijing-strain-derived MTBVAC-L2 was found
to be the least attenuated candidate and only MTBVAC constructed
from lineage 4 was more attenuated than BCG Pasteur. Some pheno-
types specific to Beijing strains might have contributed to this finding.
The presence of phenolic glycolipids in Beijing strains, which is different
to L4 strains due to a frameshift mutation in the pks15/1 gene [59], are
linked to inhibition of innate immune responses and higher virulence of
the Beijing family [60]. Moreover, in this work, we explored another dif-
ferential phenotype between the three vaccine candidates, linked to
PE_PGRS secretion. Indeed, MTBVAC-L2 failed to secrete PE_PGRS pro-
teins in contrast to MTBVAC and MTBVAC-L3. Since lack of secretion of
these proteins has been associated with increased virulence in mice
[53], this phenotype might also contribute to the lower attenuation of
MTBVAC-L2 observed in SCID mice.
Zhang and colleagues recently demonstrated a marked heteroge-
neity in attenuation and protective efficacy among 13 different BCG
sub-strains in mice [61]. Results from this study suggest a correlation
between a higher protection conferred by those BCG strains which
were less attenuated and vice versa [61]. Supporting differences in
protective efficacy across BCG strains, we also observed that BCG
Danish conferred less protection than MTBVAC in the C3H/HeNRj
strain [32], albeit BCG Pasteur induces equivalent protection as
MTBVAC vaccines in this model (Fig. 4a). However, our results
obtained with the three MTBVAC derivatives, show that different lev-
els of attenuation in SCID mice do not necessarily predict vaccine effi-
cacy in immune-competent mice, as no clear association between
attenuation and protection was found. It is important to mention
nevertheless, that the dosage and inoculation routes differ between
both studies, which might explain the differences in the time-to-
humane endpoint durations after vaccination with BCG sub-strains
or MTBVAC derivatives.
Our protective efficacy experiments against modern M. tuberculo-
sis strains suggest no lineage-dependent protection in C3H/HeNRj
mice, although additional protection experiments using different
vaccination regimes or additional animal models might provide a
more detailed insight on this topic. This similar protective efficacy
might be related to the presence of the complete antigenic repertoire
of M. tuberculosis across MTBVAC vaccines, which is thought to result
Fig. 4. Protective efficacy of MTBVAC, MTBVAC-L2 and MTBVAC-L3 in C3H/HeNRj mice against challenge with strains from modern lineages ofM. tuberculosis. The graphs represent
bacterial burden in lungs (left panels) and spleen (right panels) from groups of 6 mice subcutaneously immunized with the corresponding vaccine and after a 4 weeks intranasal
challenge against (a) H37Rv (lineage 4 strain), (b) W4-Bejiing (lineage 2 strain) and (c) HCU3524 (lineage 3 strain). All data are mean § SEM. Asterisks indicate * p < 0.05, **
p < 0.01, *** p < 0.001 and **** p < 0.0001 [One-way ANOVA, Bonferroni post-test].
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protection was conferred by MTBVAC and MTBVAC-L2 compared to
BCG Pasteur against challenge with W4-Beijing strain. Beijing strains
have been associated to recent TB outbreaks, hyper-virulent pheno-
types and drug resistance [62]. One hypothesis for this successfully
emergence of L2 strains could be the ability of these strains to escape
from BCG vaccination, although this remains elusive because of the
controversial conclusions in different epidemiological studies [63]. It
is noteworthy that MTBVAC vaccines conferred improved protection
against a challenge with the W4-Beijing strain, which is an important
finding, even in the light that the MTBVAC-L2 vaccine strain appeared
slightly less attenuated than other vaccines in mouse experiments.Our previous preclinical studies demonstrated that MTBVAC pro-
tected against challenge with H37Rv in mice [19] or with Erdman in
non-human primates [36], both strains belonging to the lineage 4.
Importantly, here we show for the first time that MTBVAC vaccine
candidates are able to protect against different representatives of the
modern lineages of M. tuberculosis in mice. This finding represents an
important detail for the clinical evaluation of MTBVAC and putative
new live attenuated vaccines based on phoP and fadD26 deletions.
Since the three MTBVAC vaccine candidates provide different rela-
tive levels of protection against challenge with modern M. tuberculo-
sis strains, this suggests that the properties of the infecting strain or
their distribution in different parts of the world may determine the
I. Perez et al. / EBioMedicine 55 (2020) 102761 9efficacy of the vaccine used in humans. MTBVAC is today in Phase IIa
in adults and newborns and the results presented here further sup-
port its progress into clinical efficacy trials. In such efficacy studies,
we should be prepared for two possible scenarios. Either the original
MTBVAC constructed in the lineage 4 background might confer
equivalent protection independently of the vaccinated population; or
alternatively, MTBVAC or the new MTBVAC-L2 and MTBVAC-L3 con-
structed in this work might confer efficacious protection in popula-
tions where strains from lineages 4, 2 or 3 are the most prevalent,
respectively. In this latter scenario, the three MTBVAC vaccines could
be combined into a polyvalent vaccine that affords a worldwide pro-
tection against TB. Altogether, our results not only expand the cur-
rent knowledge of the MTBVAC vaccine but anticipate novel
MTBVAC-based strategies for the future.
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